免疫チェックポイント阻害薬関連胃腸炎の内視鏡診断とマネージメント

Yasuo Hamamoto

doi:10.11280/gee.64.1083

免疫チェックポイント阻害薬関連胃腸炎の内視鏡診断とマネージメント

Translated title of the contribution: ENDOSCOPIC FINDINGS AND MANAGEMENTS OF IMMUNE CHECKPOINT INHIBITOR-RELATED GASTROINTESTINAL DISORDER

Yasuo Hamamoto

Oncology Center

Research output: Contribution to journal › Review article › peer-review

Abstract

Immune checkpoint inhibitors (ICIs) exert antitumor effects by inducing the immune response to tumor cells; however, this also leads to an increased incidence of immune-related adverse events (irAEs). Enteritis is the most common irAE caused by anti-CTLA-4 antibodies, and its frequency and pathophysiology vary based on the combination of ICIs and other antitumor drugs (cell-mediated anticancer or molecular target drugs). Enteritis is therefore considered an irAE that requires special attention. The following section outlines the recent findings.

Translated title of the contribution	ENDOSCOPIC FINDINGS AND MANAGEMENTS OF IMMUNE CHECKPOINT INHIBITOR-RELATED GASTROINTESTINAL DISORDER
Original language	Japanese
Pages (from-to)	1083-1088
Number of pages	6
Journal	GASTROENTEROLOGICAL ENDOSCOPY
Volume	64
Issue number	5
DOIs	https://doi.org/10.11280/gee.64.1083
Publication status	Published - 2022 May

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging
Gastroenterology

Access to Document

10.11280/gee.64.1083

Cite this

@article{1dccab82bb6d4642a015037603356a1b,

title = "免疫チェックポイント阻害薬関連胃腸炎の内視鏡診断とマネージメント",

abstract = "Immune checkpoint inhibitors (ICIs) exert antitumor effects by inducing the immune response to tumor cells; however, this also leads to an increased incidence of immune-related adverse events (irAEs). Enteritis is the most common irAE caused by anti-CTLA-4 antibodies, and its frequency and pathophysiology vary based on the combination of ICIs and other antitumor drugs (cell-mediated anticancer or molecular target drugs). Enteritis is therefore considered an irAE that requires special attention. The following section outlines the recent findings.",

author = "Yasuo Hamamoto",

year = "2022",

month = may,

doi = "10.11280/gee.64.1083",

language = "Japanese",

volume = "64",

pages = "1083--1088",

journal = "GASTROENTEROLOGICAL ENDOSCOPY",

issn = "0387-1207",

publisher = "Japan Gastroenterological Endoscopy Society",

number = "5",

}

TY - JOUR

T1 - 免疫チェックポイント阻害薬関連胃腸炎の内視鏡診断とマネージメント

AU - Hamamoto, Yasuo

PY - 2022/5

Y1 - 2022/5

N2 - Immune checkpoint inhibitors (ICIs) exert antitumor effects by inducing the immune response to tumor cells; however, this also leads to an increased incidence of immune-related adverse events (irAEs). Enteritis is the most common irAE caused by anti-CTLA-4 antibodies, and its frequency and pathophysiology vary based on the combination of ICIs and other antitumor drugs (cell-mediated anticancer or molecular target drugs). Enteritis is therefore considered an irAE that requires special attention. The following section outlines the recent findings.

AB - Immune checkpoint inhibitors (ICIs) exert antitumor effects by inducing the immune response to tumor cells; however, this also leads to an increased incidence of immune-related adverse events (irAEs). Enteritis is the most common irAE caused by anti-CTLA-4 antibodies, and its frequency and pathophysiology vary based on the combination of ICIs and other antitumor drugs (cell-mediated anticancer or molecular target drugs). Enteritis is therefore considered an irAE that requires special attention. The following section outlines the recent findings.

UR - http://www.scopus.com/inward/record.url?scp=85138542482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85138542482&partnerID=8YFLogxK

U2 - 10.11280/gee.64.1083

DO - 10.11280/gee.64.1083

M3 - Review article

AN - SCOPUS:85138542482

SN - 0387-1207

VL - 64

SP - 1083

EP - 1088

JO - GASTROENTEROLOGICAL ENDOSCOPY

JF - GASTROENTEROLOGICAL ENDOSCOPY

IS - 5

ER -

免疫チェックポイント阻害薬関連胃腸炎の内視鏡診断とマネージメント

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this